Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol]
|
|
- Madeleine Briggs
- 6 years ago
- Views:
Transcription
1 Página 1 de 7 Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM. This protocol should be cited as: Kalantaridou SN, Calis KA, Nelson LM.. Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 2, Oxford: Update Software. Background Present menopausal hormone replacement therapy regimens were designed for women who experience ovarian failure (normal menopause) around age 50. Postmenopausal women who take hormone replacement therapy prolong their exposure to estrogen beyond the average age of completion of their reproductive phase. At least 1% of women, however, experience premature ovarian failure before the age of 40, and optimal hormone replacement therapy regimens should be established for these younger women (Coulam 1986). For example, compared with normal postmenopausal women, women with premature ovarian failure need higher doses of estrogen to control menopausal symptoms. A prospective, randomised, controlled study showed that estrogen replacement therapy prevents bone loss in postmenopausal women (PEPI trial 1996). Furthermore, a prospective cohort study and a case-control study have shown that estrogen replacement decreases the risk for fractures in postmenopausal women (Cauley 1995; Michaelsson 1998). Nonetheless, in a small study, the recognized bone-sparing dose of mg of conjugated estrogen (Lindsay 1984) failed to prevent vertebral bone loss in premenopausal women made estrogen-deficient by gonadotropin-releasing hormone agonist therapy (Sugimoto 1993). Also, available evidence suggests that the usual menopausal hormone replacement therapy is not adequate to protect young women with premature ovarian failure from developing osteoporosis (Anasti 1998). Two-thirds of women with premature ovarian failure have femoral neck bone mineral density more than one standard deviation below the mean of similar age women with normal ovarian function, despite taking estrogen replacement therapy (Anasti 1998). Also, a prospective study has shown (Cummings 1993) that a femoral neck bone mineral density more than one standard deviation below the mean of age-matched controls predicts a 2.6-fold increased risk of hip fracture. The findings of these two studies suggest that two-thirds of women with premature ovarian failure may be at increased risk for hip fracture despite taking estrogen replacement. Premature ovarian failure is a condition that causes amenorrhea, elevated gonadotropins, hypoestrogenemia (Kalantaridou 1998) and hypoandrogenemia (Bermudez 1993). Young women can experience ovarian failure by several mechanisms, including karyotypic abnormalities, autoimmunity, radiation or chemotherapy, and surgical castration. In most cases the cause of premature ovarian failure is unknown (karyotypically normal spontaneous premature ovarian failure). Women with premature ovarian failure are at higher risk for cardiovascular disease compared to naturally menopausal women (Van der Schouw 1996; Jacobsen 1997). Also, women with premature ovarian failure have a nearly twofold agespecific increase in mortality rate compared to naturally menopausal women (Snowdon 1989; Cooper 1998). The aim of this review is to evaluate evidence from randomised controlled trials, if any, that hormone replacement (estrogen/progestin, estrogen/androgen/progestin or other types of hormone replacement strategies, such as for example tibolone) can maintain bone mass of women with spontaneous premature ovarian failure.
2 Página 2 de 7 Objectives To investigate whether the use of hormone replacement therapy can restore bone mass in young women with premature ovarian failure. We will test the hypothesis that "hormone replacement therapy (estrogen/progestin, estrogen/androgen/progestin or other types of hormone replacement strategies, such as for example tibolone) maintains bone of women with spontaneous premature ovarian failure. Secondary hypotheses will include: "hormone replacement therapy (estrogen/progestin, estrogen/androgen/progestin or other types of hormone replacement strategies, such as for example tibolone) can: 1) treat symptoms of sex steroid deficiency (such as hot flashes, night sweats, dyspareunia, e.t.c.), 2) decrease heart disease risk factors, 3) restore sexual function, and 4) restore cognitive function in women with premature ovarian failure". Criteria for considering studies for this review Types of studies Randomised controlled studies will be considered for inclusion in this review if they evaluate the effect of hormone replacement on bone mineral density and/or fractures of women with spontaneous premature ovarian failure. Only double blind randomised controlled studies will be considered suitable for inclusion. Randomised controlled studies evaluating the effect of hormone replacement on symptoms of sex steroid deficiency, heart disease risk factors, sexual or cognitive function in young women with premature ovarian failure will be considered as well. Types of participants Women with spontaneous premature ovarian failure and normal chromosomes receiving hormone replacement therapy. Criteria for karyotypically normal spontaneous premature ovarian failure: 1. Age > 18 and < 40 years 2. Two FSH levels > 40 miu/ml (at least one month apart) 3. Amenorrhea for at least four months 4. No evidence of genetic, metabolic, toxic, or iatrogenic cause of the ovarian failure Types of intervention Randomised controlled studies investigating the effect of hormone replacement (estrogen/progestin/androgen, or other types of hormone replacement strategies, such as for example tibolone; administered by all routes, i.e. orally and/or parenterally) on bone mineral density and/or fractures of women with premature ovarian failure will be considered suitable for inclusion in this review. All the randomised controlled studies with bone densitometry (measured by DEXA, DPA, etc) will be included. Studies investigating the effect of hormone replacement on symptoms of sex steroid deficiency, heart disease risk factors, cognitive or sexual function will be considered as well. One year should be the minimum length of the trials. Groups to be compared: 1. women with spontaneous premature ovarian failure receiving estrogen/progestin (or other types of hormone replacement strategies, such as for example tibolone)
3 Página 3 de 7 replacement compared with women with spontaneous premature ovarian failure receiving estrogen/androgen/progestin replacement 2. women with premature ovarian failure receiving estrogen/progestin (or other types of hormone replacement strategies, such as for example tibolone) replacement compared with women premature ovarian failure receiving placebo (or no treatment) 3. women with premature ovarian failure receiving estrogen/androgen/progestin replacement compared with women with premature ovarian failure receiving placebo (or no treatment). Types of outcome measures Studies will be considered suitable for inclusion in this review if they evaluate any of the following outcome measures in women with spontaneous premature ovarian failure receiving hormone replacement: Spinal bone mineral density (L2-4) and/or hip bone mineral density (femoral neck, trochanter, Ward's triangle, total hip) Vertebral and/or hip fracture rates Symptoms of sex-steroid deficiency (such as hot flashes, night sweats, dyspareunia), Heart disease risk factors (i.e. total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, body composition) Sexual and cognitive function In addition, any other outcome assessed in the trials will be considered as well. Search strategy for identification of studies The literature search will be limited initially to those studies reported in English. Trials reported in a foreign language will be sought over time as resources permit. All publications which describe randomised, controlled trials investigating the effect of hormone replacement on bone mineral density, symptoms of sex-steroid deficiency, heart disease risk factors, sexual and cognitive function of women with premature ovarian failure will be obtained using the search strategy developed by the Menstrual Disorders and Subfertility Group for MEDLINE and handsearching of specialist journals and examination of review articles (see Review Group details for more information). The reviewers will also search the electronic database EMBASE. In addition, the following terms and variations of these terms will be included: premature ovarian failure premature menopause hormone replacement therapy estrogens progestogens androgens tibolone Reference lists of included and excluded studies will be inspected. Investigators conducting randomised controlled trials examining the safety and efficacy of hormone replacement therapy in women with premature ovarian failure will be contacted to obtain study data and details of subsequent journal publication. Methods of the review The selection of trials for inclusion in the review will be undertaken by two reviewers (SNK and KAC) employing the search strategy described above. A third reviewer (LMN) will assess any trials where there will be uncertainty regarding eligibility. All the reviewers are experienced in clinical issues.
4 Página 4 de 7 An assessment of the quality of trials and data extraction will be performed independently by the three reviewers (SNK, KAC, LMN) using forms designed according to the Cochrane guidelines. Any discrepancies will be resolved by discussion. When necessary, additional information on trial methodology or actual original data will be sought from the principal author of any trials that appear to meet the eligibility criteria. Included trials will be analysed for the following quality criteria and methodological details: a) Method of randomizations; blinding; number of patients randomised, excluded, or lost to follow up; reporting of the outcome of all the women enrolled and whether the trial was single or multicentered; the presence of power calculation; duration of the study; sources of any funding. b) Information on the trial participants included age, number of years since the development of ovarian failure, exclusion criteria. c) Interventions used: types of therapeutic agent used, dose, duration, and timing of administration of therapeutic agents used. d) Outcomes: 1. Outcomes relevant to this analysis (e.g. changes in bone mineral density, changes in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, body composition, sexual and cognitive function). Bone mineral density is the principal outcome measure. 2. Primary outcomes of the trial, which may differ from the outcomes relevant to this analysis 3. Adverse effects due to hormone replacement therapy will be recorded (such as endometrial hyperplasia and breast cancer). Major quality criteria will be given a ranking to enable sensitivity analyses. Results from trials using estrogen/progestin, estrogen/androgen/progestin, tibolone will be analysed separately. Dosages will be broken down for analysis as well. Sensitivity analysis will be performed according to randomizations quality, control group comparison (either placebo or no treatment), equality at baseline, rate of withdrawal and losses to follow-up, intention to treat analysis, and length of treatment period. Statistical analysis will be performed in accordance with the guidelines for statistical analysis developed by the Menstrual Disorders and Subfertility Group as it applies to continuous outcomes. Heterogeneity between the results of different studies will be examined by inspecting the scatter in data points and the overlap in their confidence intervals and by checking the results of the chi-squared tests. If the randomised controlled studies have different length of therapy, subgroup analysis will be performed. We will combine placebo- and no-treatment studies. These studies will be analysed separately as subgroups. This review will include eligible trials that are retrievable as of April Subsequent eligible trials will be included in an update of this review. Acknowledgements Potential conflict of interest None known References Additional references
5 Página 5 de 7 Anasti 1998 Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstetrics and Gynecology 1998;91:12-5. Bermudez 1993 Bermudez JA, Moran C, Herrera J, Barahona E, Perez MC, Zarate A. Determination of the steroidogenic capacity in premature ovarian failure. Fertility and Sterility 1993;60: Cauley 1995 Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of osteoporotic fractures research group. Annals of Internal Medicine 1995;122:9-16. Cooper 1998 Cooper GS, Sandler DP. Age at natural menopause and mortality. Annals of Epidemiology 1998;8: Coulam 1986 Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstetrics and Gynecology 1986;67: Cummings 1993 Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-5. Jacobsen 1997 Jacobsen BK, Nilssen S, Heuch I, Kvale G. Does age at natural menopause affect mortality from ischemic heart disease?. Journal of Clinical Epidemiology 1997;50: Kalantaridou 1998 Kalantaridou SN, Davis SR, Nelson LM. Premature ovarian failure. Endocrinology and Metabolism Clinics of North America 1998;27: Lindsay 1984 Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstetrics and Gynecology 1984;63: Michaelsson 1998 Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S. Hormone replacement therapy and risk of hip fracture:
6 Página 6 de 7 population based case control study. The Swedish Hip Fracture Study Group. British Medical Journal 1998;316: PEPI trial 1996 The Writing Group for the PEPI trial. Effects of hormone therapy on bone mineral density. Results from the postmenopausal estrogen/progestin interventions (PEPI) Trial. The Journal of the American Medical Association 1996;276: Snowdon 1989 Snowdon DA, Kane RL, Beeson WL, Burke GL, Sprafka JM, Potter J, Iso H, Jacobs DR Jr, Phillips RL. Is natural menopause a biologic marker of health and aging?. American Journal of Public Health 1989;79: Sugimoto 1993 Sugimoto AK, Hodsman AB, Nisker JA. Long-term gonadotropin-releasing hormone agonist with standard postmenopausal estrogen replacement failed to prevent vertebral bone loss in premenopausal women. Fertility and Sterility 1993;60: Van der Schouw 1996 Van der Schouw YT, Van der Graaf Y, Steyerberg EW, Eijkemans MJC, Banga JD. Age at menopause as a risk for cardiovascular mortality. Lancet 1996;347: Cover sheet Hormone replacement therapy in young women with karyotypically normal spontaneous premature ovarian failure Reviewer(s) Contribution of Reviewer(s) Kalantaridou SN, Calis KA, Nelson LM. Sophia N. Kalantaridou: Took the lead in writing the protocol, developed objectives, selection criteria, methods and background. Karim A. Calis: Contributed to background section. Developed and performed search strategy. Lawrence M. Nelson: Conceptualised and edited the protocol. Issue protocol first published Date of last minor amendment Date of last substantive amendment Most recent changes 2001 issue 4 Information not supplied by reviewer 05 August 2001 Information not supplied by reviewer
7 Página 7 de 7 Review expected to be published in: Contact address Cochrane Library number Editorial group Editorial group code Issue 4, 2003 Ms Sophia Kalantaridou Kosti Palama 3 Ioannini GREECE 5042 Telephone: Facsimile: Kalantas@exchange.nih.gov CD Cochrane Menstrual Disorders and Subfertility Group MENSTR
Criteria for considering studies for this review
Página 1 de 6 Ovulation induction in women with spontaneous premature ovarian failure [protocol] Kalantaridou SN, Calis KA, Nelson LM This protocol should be cited as: Kalantaridou SN, Calis KA, Nelson
More informationMenopause and HRT. John Smiddy and Alistair Ledsam
Menopause and HRT John Smiddy and Alistair Ledsam Menopause The cessation of menstruation Diagnosed retrospectively after 1 year of amenorrhoea Average age 51 in the UK Normal physiology - Menstruation
More informationEffective Health Care Program
Comparative Effectiveness Review Number 17 Effective Health Care Program Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women Executive Summary Background Breast cancer
More informationPremature Menopause : Diagnosis and Management
Guideline Number 3 : August 2010 Premature Menopause : Diagnosis and Management Introduction : Premature menopause is a serious condition that affects young women and remains an enigma. The challenges
More informationOVERVIEW WOMEN S HEALTH: YEAR IN REVIEW
OVERVIEW WOMEN S HEALTH: YEAR IN REVIEW Judith Walsh, MD, MPH Professor of Medicine UCSF Update in Women s Health for SGIM Drs. Mary Beattie and Pam Charney Review of literature from March, 2008 through
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More information06-Mar-17. Premature menopause. Menopause. Premature menopause. Menstrual cycle oestradiol. Premature menopause. Prevalence ~1% Higher incidence:
Menopause Dr Sonia Davison MBBS FRACP PhD Endocrinologist and Clinical Fellow, Jean Hailes for Women s Health Women s Health Research Program, Monash University = the last natural menstrual period depletion
More informationThe Study of Tamoxifen and Raloxifene (STAR): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s The Study of Tamoxifen
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationHormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals
Hormones and Healthy Bones Joint Project of National Osteoporosis Foundation and Association of Reproductive Health Professionals Literature Review (January 2009) Hormone Therapy for Women Women's Health
More informationPremature Ovarian Failure: Is there a role for steroids? A randomized, double-blind, placebo-controlled trial.
Premature Ovarian Failure: Is there a role for steroids? A randomized, double-blind, placebo-controlled trial. Rebecca Fenichel A. Study Purpose and Rationale Premature ovarian failure is a condition causing
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationManagement of Patients With Premature Ovarian Insufficiency
Management of Patients With Premature Ovarian Insufficiency Prof. Dr. H. Cavidan Gülerman Sağlık Bilimleri Üniversitesi Ankara Dr. Zekai Tahir Burak SUAM XII. Türk Alman Jinekoloji Kongresi 28 Nisan 2018
More informationHormones friend or foe? Undertreatment and quality of life. No conflicts of interest to declare
Hormones friend or foe? Undertreatment and quality of life Anette Tønnes Pedersen MD, Ph.D. Consultant, Associate professor Dept. Of Gynecology / Fertility Clinic Rigshospitalet No conflicts of interest
More informationHRT and bone health. Management of osteoporosis and controversial issues. Delfin A. Tan, MD
Strong Bone Asia V. Osteoporosis in ASEAN (+), Danang, Vietnam, 3 August 2013 Management of osteoporosis and controversial issues HRT and bone health Delfin A. Tan, MD Section of Reproductive Endocrinology
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationMenopause management NICE Implementation
Menopause management NICE Implementation Dr Paula Briggs Consultant in Sexual & Reproductive Health Southport and Ormskirk NHS Hospital Trust Why a NICE guideline (NG 23) Media reports about HRT have not
More informationWHI Estrogen--Progestin vs. Placebo (Women with intact uterus)
HORMONE REPLACEMENT THERAPY In the historical period it was commonly held that estrogen had two principal benefits to postmenopausal women: 1) To alleviate the constitutional symptoms related to the climacteric
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationÓ Journal of Krishna Institute of Medical Sciences University 62
ISSN 2231-4261 ORIGINAL ARTICLE Lipid Profile in Subfertile Clients with Premature Ovarian Failure: University of Ilorin Teaching Hospital Experience 1* 1 1 2 3 I.M AbdulAzeez, S.A Biliaminu, A.B Okesina,
More informationSERMS, Hormone Therapy and Calcitonin
SERMS, Hormone Therapy and Calcitonin Tiffany Kim, MD Clinical Fellow VA Advanced Women s Health UCSF Endocrinology and Metabolism I have nothing to disclose Thanks to Clifford Rosen and Steven Cummings
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationOSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC
OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre
More informationHRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College
HRT in Perimenopausal Women Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College 1 This is the Change But the CHANGE is not a disease 2 Introduction With a marked increase in longevity, women now
More informationA Tale of Three Hormones: hcg, Progesterone and AMH
A Tale of Three Hormones: hcg, Progesterone and AMH Download the Ferring AR ipad/iphone app from the Apple Store: http://bit.ly/1okk74m Human Ovarian Steroidogenesis and Gonadotrophin Stimulation Johan
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationIntegrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options
Paris, November 1st 2016 Integrated care: guidance on fracture prevention in cancer-associated bone disease; treatment options René Rizzoli MD International Osteoporosis Foundation and Division of Bone
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG PG Cert. Advanced Gynaecology Endoscopy Consultant Gynaecologist Heart of England NHS Foundation Trust Spire Parkway
More informationBreast Cancer and Bone Loss. One in seven women will develop breast cancer during a lifetime
Breast Cancer and Bone Loss One in seven women will develop breast cancer during a lifetime Causes of Bone Loss in Breast Cancer Patients Aromatase inhibitors Bil Oophorectomy Hypogonadism Steroids Chemotherapy
More informationInternational Journal of Research and Review E-ISSN: ; P-ISSN:
International Journal of Research and Review www.gkpublication.in E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Risk Assessment of Osteoporosis in Postmenopausal Women Dr Savita Tamaria
More informationPost-menopausal hormone replacement therapy. Evan Klass, MD May 17, 2018
Post-menopausal hormone replacement therapy Evan Klass, MD May 17, 2018 Are we really still talking about this? Are we really still talking about this? 1960-1975- estrogen prescriptions doubled. Pharma
More informationVirtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11
Virtual Mentor Ethics Journal of the American Medical Association November 2005, Volume 7, Number 11 Clinical Pearl Post Women's Health Initiative Menopausal Women and Hormone Therapy by JoAnn V. Pinkerton,
More informationAusPharm CE Hormone therapy 23/09/10. Hormone therapy
Hormone therapy Learning objectives: Assess options to address quality of life and health concerns of menopausal women Outline indications for hormone therapy Counsel women on the risks and benefits of
More informationMs. Y. Outline. Updates of SERMs and Estrogen
Ms. Y Updates of SERMs and Estrogen Steven R. Cummings, MD, FACP San Francisco Coordinating Center CPMC Research Institute and UCSF Support from Lilly, Pfizer, Berlex 55 y.o. woman with mild hypertension
More informationHormone Treatments and the Risk of Breast Cancer
Cornell University Program on Breast Cancer and Environmental Risk Factors in New York State (BCERF) Updated July 2002 Hormone Treatments and the Risk of Breast Cancer 1) Hormone Treatment After Menopause
More informationThe Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal Symptoms and Postmenopausal Osteoporosis
Curr Obstet Gynecol Rep (2012) 1:50 58 DOI 10.1007/s13669-012-0007-6 MANAGEMENT OF MENOPAUSE (K-E HUANG, SECTION EDITOR) The Tissue-Selective Estrogen Complex (TSEC): A Promising New Therapy for Menopausal
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More informationREVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES
REVIEW POSSIBLE DELETION OF MEDROXYPROGESTERONE FROM THE 14 TH WHO MODEL LIST OF ESSENTIAL MEDICINES Author: Lenita Wannmacher Application: To perform a quick review of medroxyprogesterone acetate tablet
More informationEstrogen and progestogen therapy in postmenopausal women
Estrogen and progestogen therapy in postmenopausal women The Practice Committee of the American Society for Reproductive Medicine American Society for Reproductive Medicine, Birmingham, Alabama Hormone
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More information2. The effectiveness of combined androgen blockade versus monotherapy.
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer Blue Cross and Blue Shield Association, Aronson N, Seidenfeld J Authors' objectives
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationThe British Menopause Society and Women s Health Concern recommendations on the management of women with premature ovarian insufficiency
Review The British Menopause Society and Women s Health Concern recommendations on the management of women with premature ovarian insufficiency Post Reproductive Health 2017, Vol. 23(1) 22 35! The Author(s)
More informationThis includes bone loss, endometrial cancer, and vasomotor symptoms.
Hello and welcome. My name is Chad Barnett. I m a Clinical Pharmacy Specialist in the Division of Pharmacy at the University of Texas, MD Anderson Cancer Center and I m very pleased today to be able to
More informationOral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis
Oral Alendronate Vs. Three-Monthly Iv Ibandronate In The Treatment Of Postmenopausal Osteoporosis Miriam Silverberg A. Study Purpose and Rationale More than 70% of fractures in people after the age of
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Predicting the menopause The menopause marks the end of ovarian follicular activity and is said to have occurred after 12 months amenorrhoea. The average age of the menopause is between 45 and 60 years
More informationEstrogens and progestogens
Estrogens and progestogens Estradiol and Progesterone hormones produced by the gonads are necessary for: conception embryonic maturation development of primary and secondary sexual characteristics at puberty.
More informationEfficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study
Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:
More informationCARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME
CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME Enrico Carmina Executive Director & CEO of Androgen Excess & PCOS Society Professor of Endocrinology Department of Health Sciences and Mother and Child
More informationOutline. Estrogens and SERMS The forgotten few! How Does Estrogen Work in Bone? Its Complex!!! 6/14/2013
Outline Estrogens and SERMS The forgotten few! Clifford J Rosen MD rosenc@mmc.org Physiology of Estrogen and estrogen receptors Actions of estrogen on bone BMD, fracture, other off target effects Cohort
More informationHormonal Control of Human Reproduction
Hormonal Control of Human Reproduction Bởi: OpenStaxCollege The human male and female reproductive cycles are controlled by the interaction of hormones from the hypothalamus and anterior pituitary with
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationPrijevremena insuficijencija jajnika (dijagnoza, terapija, socijalno zamrzavanje) / Premature ovarian failure (diagnosis, therapy, social freezing)
Prijevremena insuficijencija jajnika (dijagnoza, terapija, socijalno zamrzavanje) / Premature ovarian failure (diagnosis, therapy, social freezing) Miro Šimun Alebić -50000 folikula Mahajan N. Fertility
More informationGynecologists are first-line providers for
Update OSTEOPOROSIS A new agent, and new understandings of old drugs, top the year s developments in bone health Steven R. Goldstein, MD Dr. Goldstein is Professor, Department of Obstetrics and Gynecology,
More informationManaging menopause in Primary Care and recent advances in HRT
Managing menopause in Primary Care and recent advances in HRT Raj Saha, MD, DMRT, FRCOG Consultant Gynaecologist Heart of England NHS Foundation Trust rajsaha1@yahoo.co.uk Content of today s talk Aims
More informationT A B L E O F C O N T E N T S
Short-term psychodynamic psychotherapies for anxiety, depression and somatoform disorders (Unknown) Abbass AA, Hancock JT, Henderson J, Kisely S This is a reprint of a Cochrane unknown, prepared and maintained
More informationSerum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women
Maturitas 50 (2005) 19 29 Serum estrogen level after hormone replacement therapy and body mass index in postmenopausal and bilaterally ovariectomized women Toshiyuki Yasui a,, Hirokazu Uemura a, Yuka Umino
More informationUse of Low Potency Estrogens Does Not Reduce the Risk of Hip Fracture
Bone Vol. 30, No. 4 April 2002:613 618 Use of Low Potency Estrogens Does Not Reduce the Risk of Hip Fracture K. MICHAËLSSON, 1 J. A. BARON, 2 B. Y. FARAHMAND 3 and S. LJUNGHALL 4 1 Department of Orthopaedics,
More informationPostmenopausal hormone therapy and cancer risk
International Congress Series 1279 (2005) 133 140 www.ics-elsevier.com Postmenopausal hormone therapy and cancer risk P. Kenemans*, R.A. Verstraeten, R.H.M. Verheijen Department of Obstetrics and Gynaecology,
More informationA response by Servier to the Statement of Reasons provided by NICE
A response by Servier to the Statement of Reasons provided by NICE Servier gratefully acknowledges the Statement of Reasons document from NICE, and is pleased to provide information to assist NICE in its
More informationDINE AND LEARN ENDOCRINOLOGY PEARLS. Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC
DINE AND LEARN ENDOCRINOLOGY PEARLS Dr. Priya Manjoo, MD, FRCPC Endocrinology, Victoria, BC OUTLINE HRT and CVD HRT and Breast Cancer Osteoporosis When to treat How long to treat for Bisphosphonates BMD
More informationDrug Class Review on Estrogens
Drug Class Review on July 2004 Heidi D. Nelson, MD, MPH Peggy Nygren, MA Michele Freeman, MPH Benjamin K. S. Chan, MS Oregon Evidence-based Practice Center Oregon Health & Science University TABLE OF CONTENTS
More informationAuthors' objectives To evaluate the efficacy of complementary and alternative therapies for the management of menopausal symptoms.
Complementary and alternative therapies for the management of menopause-related symptoms: a systematic evidence review Nedrow A, Miller J, Walker M, Nygren P, Huffman L H, Nelson H D CRD summary This review
More informationPROSPECTIVE STUDIES HAVE
ORIGINAL CONTRIBUTION Serum Estradiol Level and Risk of Breast Cancer During Treatment With Steven R. Cummings, MD Tu Duong, MA Emily Kenyon, PhD Jane A. Cauley, DrPH Malcolm Whitehead, MB,BS, FRCOG Kathryn
More informationORIGINAL INVESTIGATION
Parathyroid Hormone for Treatment of Osteoporosis Carolyn Crandall, MD ORIGINAL INVESTIGATION Background: Osteoporosis is a common condition associated with multiple deleterious consequences. No therapy
More informationDrug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures. Final Report
Drug Class Review on Estrogen for Treatment of Menopausal Symptoms and Prevention of Low Bone Density & Fractures Final Report Heidi D. Nelson, MD, MPH Peggy Nygren, MA Benjamin K. S. Chan, MS Produced
More informationA cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W
A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation
More informationMenopause & HRT. Matt McKenna Elliot Davis
Menopause & HRT Matt McKenna Elliot Davis Menopause Before age 40: Premature Menopause After 12 months clinical diagnosis made Depletion of Ovarian Follicles Oestrogen Progesterone LH FSH Spontaneous Amemorrhoea
More informationTHE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY
Annu. Rev. Public Health 2005. 26:115 40 doi: 10.1146/annurev.publhealth.26.021304.144637 Copyright c 2005 by Annual Reviews. All rights reserved THE RISE AND FALL OF MENOPAUSAL HORMONE THERAPY Elizabeth
More informationAmerican Society of Clinical Oncology June , New Orleans
American Society of Clinical Oncology June 5-8 2004, New Orleans The 2004 annual meeting of the American Society of Clinical Oncology (ASCO) was held June 5 8 in New Orleans, Louisiana. This conference
More informationAsmall number of studies have examined
Appendix B: Evidence on Hormone Replacement Therapy and Fractures B Asmall number of studies have examined directly the relationship between use of hormonal replacement therapy and risk of hip fracture
More informationMedical Director Update
Medical Director Update Articles: Bone Density Test Can Predict Fractures Over Twenty-Five Years Community Awareness Bone Density Testing Program: 18 Months Experience More Attention Should Be Paid To
More informationCan we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous
Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous Distal radius fracture in women after menopause is in many cases a first clinical indication for the presence of
More informationSetting The setting was secondary care. The economic study was carried out in Sweden.
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Borgstrom F, Johnell O, Kanis J A, Oden A, Sykes D, Jonsson B Record Status This
More informationAn Evidence-based Review of Clinical Trial Data
An Evidence-based Review of Clinical Trial Data Karen K. Miller, MD Massachusetts General Hospital Harvard Medical School Boston, MA 1 Rationale for Investigating Androgen Administration in Women: Data
More informationSelective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence
Review: Clinical Trial Outcomes Selective estrogen receptor modulators in the treatment of osteoporosis: a review of the clinical evidence Clin. Invest. (2011) 1(5), 719 724 The ideal selective estrogen
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationDXA scanning to diagnose osteoporosis: Do you know what the results mean?
REVIEW CME CREDIT BRADFORD RICHMOND, MD Department of Radiology, The Cleveland Clinic; certification instructor, the International Society for Clinical Densitometry DXA scanning to diagnose osteoporosis:
More informationHORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer
HORMONE THERAPY A BALANCED VIEW?? Prof Greta Dreyer -- PART 1 -- Definitions HRT hormone replacement therapy HT genome therapy ERT estrogen replacement therapy ET estrogen EPT estrogen progesterone therapy
More informationBone mineral density testing: Is a T score enough to determine the screening interval?
Interpreting Key Trials CME CREDIT EDUCATIONAL OBJECTIVE: Readers will measure bone mineral density at reasonable intervals in their older postmenopausal patients Krupa B. Doshi, MD, CCD Department of
More informationA Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis
SH SUEN & SCS CHAN A Prospective Observational Study to Evaluate the Efficacy and Safety Profiles of Leuprorelin 3 Month Depot for the Treatment of Pelvic Endometriosis Sik Hung SUEN MBChB, MRCOG Resident
More informationExtended Adjuvant Endocrine Therapy
Extended Adjuvant Endocrine Therapy After all, 5 years Tamoxifen works.. For women with ER+ primary breast cancer, previous studies have shown that treatment with tamoxifen for 5 years has a carry-over
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationTrial: Take-Home Message: Executive Summary: Guidelines:
Trial: Davies C, et al. "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial".
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationThe Practice Committee of the American Society for Reproductive Medicine,
FERTILITY AND STERILITY VOL. 81, NO. 1, JANUARY 2004 Copyright 2004 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. PRACTICE COMMITTEE Estrogen
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationCentre for Menstrual Cycle and Ovulation Research at Eight: 2010 CeMCOR Anniversary Celebration
June 30, 2010 Centre for Menstrual Cycle and Ovulation Research at Eight: 2010 CeMCOR Anniversary Celebration by Dr. Jerilynn C. Prior, Scientific Director, Centre for Menstrual Cycle and Ovulation Research
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationW hile the headline-grabbing Women s
OBG MANAGEMENT BY ROBERT L. BARBIERI, MD New options in osteoporosis therapy: Combination and sequential treatment Perhaps the biggest medical question to emerge from the WHI study is how to best treat
More informationSystematic Review & Course outline. Lecture (20%) Class discussion & tutorial (30%)
Systematic Review & Meta-analysisanalysis Ammarin Thakkinstian, Ph.D. Section for Clinical Epidemiology and Biostatistics Faculty of Medicine, Ramathibodi Hospital Tel: 02-201-1269, 02-201-1762 Fax: 02-2011284
More informationAmerican Journal of Internal Medicine
American Journal of Internal Medicine 2016; 4(3): 49-59 http://www.sciencepublishinggroup.com/j/ajim doi: 10.11648/j.ajim.20160403.12 ISSN: 2330-4316 (Print); ISSN: 2330-4324 (Online) The Effect of Dose-Reduced
More information